Psilocybin

Subscribe to Psilocybin

Cannabis: In Focus

  • FDA and FTC Issue Cease and Desist Letters to Companies Selling Delta-8 Edibles
  • FDA Releases Draft Guidance for Psychedelic Drug Research
  • Federal Agencies Investigating Former Oregon Secretary of State’s Ties to Cannabis Company
  • “Plain” Packaging Guidelines for Missouri Cannabis Products Go Into Effect July 30

Continue Reading Cannabis Legal Report—Week of July 17, 2023

Oregon became the first state to offer controlled use of psilocybin to the public on January 1, 2023. Psilocybin is a Schedule I psychoactive substance that is illegal at the federal level. Notwithstanding this federal illegality, psilocybin’s potential medical uses are being explored in medical research centers, and the substance is currently undergoing clinical trials…

Cannabis: In Focus

  • New York City Attempts to Crack Down on Illicit Cannabis Market
  • Connecticut Launches Recreational Cannabis Sales, With More States Expected to Follow in 2023
  • Psilocybin State Updates
  • FDA Issues Three New Warning Letters to CBD Product Manufacturers Alleging COVID-19 Benefits
  • Congressional Research Service: Cannabis Banking and the Federal Reserve

Continue Reading Cannabis Legal Report—Week of January 23, 2023

Millions of Americans are utilizing medical cannabis and psilocybin to treat specific medical conditions each day. However, scientific and medical research lags in the U.S. lags behind other nations. Dr. Stephen M. Dahmer, Chief Medical Officer at Vireo Health, and Betty Aldworth, Director of Communications and Events at the Multidisciplinary Association for Psychedelic Studies (MAPS)…